Real-World Evidence and Market Access Symposium Features Timely Advisement During COVID Era

April 16, 2021 12:36:28
  • Organized by Dynamic Global Events (“DGE”), a market research and event outreach organization with experience in relevant B2B life science conferences
  • Taking place April 14-15 with an online, live-streamed format
  • Experts from some two dozen organizations and companies addressing timely real-world evidence (“RWE”) applicable to the COVID-19 pandemic’s disruptive effect on societies
  • A potential tool for preparing to transform regulatory submissions, clinical decision making and value demonstrations
Dynamic Global Events (“DGE”) will leverage its extensive market research, targeted outreach and content-driven team’s experience to deliver the latest in a series of relevant B2B events within the life sciences arena, focusing on data analytics during the two-day Real-World Evidence & Market Access Symposium. The symposium will take place April 14 and 15, involving a livestream audience with interests in clinical applications and the lessons derived from using real-world evidence (“RWE”) during the ongoing COVID-19 pandemic. The novel nature of the pandemic also made it necessary for scientists to continually re-evaluate their findings in order to issue the best advisory information to the public. But the pandemic’s disruptive forces have also opened the door to significant new developments in the life sciences arena that might have been unthought of just a couple of years ago, including strategies on how to develop confidence in unfolding science. DGE’s Real World Evidence and Market Access Symposium addresses topics such as applying RWE to communications strategies to achieve launch excellence, establishing what evidence can support new indications or labeling, informing clinical trial design innovation and precise patient targeting and screening, developing the potential of AI and machine learning to predict, diagnose, treat and prevent disease, and using RWE to support product effectiveness for payers and prescribers, as well as improving reimbursement models. The symposium’s insights will prove particularly useful to companies and organizations in helping them to prepare for potential FDA 2021 draft guidance on real-world evidence. More than two dozen speaking faculty members hailing from international biopharmaceutical companies, RWE technology platforms and research universities will broaden attendees’ understanding of immediately relevant RWE matters. For more information, visit the symposium’s web portal at To receive a discount on your registration, use code IBN2021. About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire (BMW) San Francisco, California 415.949.5050 Office BioMedWire is part of the InvestorBrandNetwork.